Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma
“Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma”, vol. 14, pp. 11944-11954, 2015.
, Two major subtypes of melanoma include cutaneous melanoma and mucosal melanoma. The latter type is rare and usually occurs in the head and neck region. High-dose interferon-α-2b (IFN-α-2b) has proven effective in the treatment of cutaneous melanoma. Recently, a regimen of temozolomide plus cisplatin was reported more likely to improve relapse-free survival and overall survival than high-dose IFN-α-2b for mucosal melanoma. We conducted this study to analyze the therapeutic effect of high-dose IFN-α-2b for patients with oral mucosal melanoma who had received prior chemotherapy.